No Data
Analysts Have Made A Financial Statement On Beauty Farm Medical and Health Industry Inc.'s (HKG:2373) Annual Report
Beauty Farm Medical and Health's Profit Rises in 2024 on 19% Revenue Jump
BEAUTYFARM MED (02373.HK): Li Fangyu has been appointed as a member of the nomination committee.
On March 26, Gelonghui announced that starting from March 26, 2025, Lian Songyong will no longer serve as a member of the Board of Directors' Nomination Committee, while Li Fangyu has been appointed as a member of the Nomination Committee to enhance the company's corporate governance and to comply with the new rules on gender diversity in nomination committees under the Securities Listing Rules of the Hong Kong Stock Exchange (which will be implemented on July 1, 2025).
BEAUTYFARM MED (02373.HK) changes its dividend policy.
On March 26, Gelonghui announced that BEAUTYFARM MED (02373.HK) does not have a fixed dividend payout ratio. After considering the company's operating performance, financial condition, cash needs, available cash, and other factors that may be relevant at the time, the company can declare dividends. While achieving steady growth in performance, the company has always attached importance to sharing its development results with its Shareholders. To effectively reward the trust of the company's Shareholders and share development results, on March 26, 2025, the Board of Directors approved the revision of the existing dividend policy. Under normal circumstances, the company will pay dividends in ordinary shares annually over the next three complete fiscal years.
Beauty Farm Announces 2024 Annual Results
Revenue and Net Profit Reached Record HighMergers and Acquisitions Integration Drove High-Quality Growth HONG KONG, March 26, 2025 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("
BEAUTYFARM MED (02373.HK) has a net income of 0.252 billion yuan in 2024, with a year-on-year growth of 9.7%.
On March 26, Gelonghui announced that BEAUTYFARM MED (02373.HK) will set new highs in business income and profits in 2024. The total revenue for the year is RMB 2.572 billion, a year-on-year increase of 19.9%. With steady growth in revenue, the scale effect becomes increasingly significant, driving the gross margin level up by 0.7 percentage points year-on-year to 46.3%, and net income rises to RMB 0.252 billion, a year-on-year increase of 9.7%. Strong financial performance and ample Cash / Money Market provide the company with the flexibility to respond to market changes, enabling it to actively engage in Global Strategy investments and integrated expansion. Earnings per share of 0.
Beauty Farm Medical and Health Industry Inc.'s (HKG:2373) 32% Jump Shows Its Popularity With Investors